Bellerophon Therapeutics, which is developing nitric oxide-based therapies for cardiopulmonary diseases, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.
Bellerophon was spun out of Ikaria in February 2014 as a special dividend to existing stockholders, shortly before Ikaria's non-biotech business was acquired by Madison Dearborn for $1.6 billion. Ikaria had originally intended to go public in November 2010 but withdrew its offering.
The Hampton, NJ-based company, which was spun out of Ikaria in 2014, plans to list on the NASDAQ under the symbol BLPH. Bellerophon Therapeutics initially filed confidentially on May 14, 2014. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
The article The 'NO' IPO: Nitric oxide biotech Bellerophon Therapeutics files for a $69 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.